[ Price : $8.95]
Outlook Therapeutics wins an appeal with FDA over its BLA for ONS-5010/Lytenava (bevacizumab-vikg), clearing a potential path towa...[ Price : $8.95]
FDA investigators cite major quality control and data integrity concerns at an Indian manufacturing facility operated by Intas Pha...[ Price : $8.95]
Dyne Therapeutics submits a BLA that seeks accelerated approval for its experimental Duchenne muscular dystrophy therapy z-rostudi...[ Price : $8.95]
FDA Matters founder Steven Grossman explains why he thinks it will take the Trump administration at least until the end of the yea...[ Price : $8.95]
Senator Tom Cotton (R-AR) urges FDA and government cybersecurity officials to review Chinese-made medical devices cleared before u...[ Price : $8.95]
A Yale Journal on Regulation article from the Yale Law School Solomon Center for Health Law & Policy examines how the Supreme Cour...[ Price : $8.95]
Biogen and Denali Therapeutics limit the development of their experimental Parkinsons disease drug BIIB122 after the therapy faile...[ Price : $8.95]
FDA approves Daiichi Sankyos Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic triple-negative bre...